comparemela.com

Xiangdong Qu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

QureBio Ltd to Present its Q-1802 Clinical Phase Ⅰ Data at 2023 ASCO-GI Meetings

/PRNewswire/ QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered.

Xiangdong quJian zhangLin shenSan franciscoUnited statesYuping sunViva bioXiaohua chenTao yuYanqiao zhangJie houLi weiYusheng wangQin yuJifang gongYakun wang

China Digest: QureBio, Galaxy Future Technology in funding news

QureBio has raised about 200 million yuan ($31 million) in its Series B round of financing.

Ting heXiangdong quDongxu huangOriza holdingsGalaxy future technologyLongmen capitalTianfu sanjiang capitalWinx capitalFuture technologyFuture capitalMatrix partners china

vimarsana © 2020. All Rights Reserved.